Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which combines semaglutide with dual amylin and calcitonin receptor agonist ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Unlock the latest advancements in obesity treatment. Expert insights reveal groundbreaking medical breakthroughs and ...

Amycretin, a once-daily oral GLP-1/Amylin co-agonist, has shown competitive weight loss percentages in early trials. The company is also developing CagriSema, a next-generation incretin-based therapy, ...

At the time, Hsieh noted that Viking’s results exceeded Wall Street expectations and outperformed Novo Nordisk’s experimental weight-loss pill, amycretin. “Notably, the 100 mg dose appears ...

Novo Nordisk A/S' CagriSema disappointed investors again, but today's update should not have surprised anyone. The flexible dosing protocol in the REDEFINE trials likely led to suboptimal efficacy ...

The pharma giant’s amycretin is a peptide engineered to activate GLP-1 and amylin receptors. In preliminary Phase 1b/2a results released in January, the highest dose of the once-weekly injection ...

Amylin, a satiety hormone, has attracted the interest of multiple drug developers. Novo’s amycretin acts on both GLP-1, the cornerstone of obesity treatment today, and amylin receptors.

Plus, it still has a promising pipeline. The stock got a boost in January after the company announced encouraging early stage trial results for amycretin, a GLP-1 drug which showed that it could ...

For instance, Novo Nordisk’s oral obesity candidate, amycretin, showed “remarkable” weight loss results in its phase 1 trial, but half of patients experienced gastrointestinal events when ...